secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001104659-22-057490
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q1 DEXTENZA revenue $12.5M (+87% YoY); net loss $12.5M; guides FY22 product rev $55-60M
--------------------------------------------------------------------------------

- DEXTENZA net product revenue $12.5M in Q1 2022, up 87% from $6.7M in Q1 2021.
- Net loss $12.5M ($0.16 basic loss per share) vs. net income $3.1M in Q1 2021; includes $7M non-cash derivative liability adjustment.
- Cash and equivalents $145.4M as of March 31, 2022; company believes sufficient through 2023.
- Guides FY2022 DEXTENZA revenue $55-60M (26-38% growth); expands commercial team with VP Steve Meyers for office setting.
- OTX-TKI Phase 1 fully enrolled, six-month data expected Q3 2022; OTX-TIC Phase 2 dosing began, triggering $2M milestone from AffaMed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922057490/0001104659-22-057490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922057490/tm2214885d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-057490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer